MVA-NP+M1 clinical trials
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses MVA-NP+M1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- MVA-NP+M1
- 7
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2017 | 2 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Barinthus Biotherapeutics (4) · University of Oxford (3)
Studies
Open first, then newest update. How each study uses MVA-NP+M1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in AdultsTerminatedPhase 2Barinthus BiotherapeuticsNCT03880474Written as MVA-NP+M1How we know
- Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge ModelCompletedPhase 2Barinthus BiotherapeuticsNCT03883113Written as MVA-NP+M1How we know
- Improved Novel VaccIne CombinaTion InflUenza StudyTerminatedPhase 2Barinthus BiotherapeuticsNCT03300362Written as MVA-NP+M1How we know
- A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1CompletedEarly Phase 1Barinthus BiotherapeuticsNCT03277456Written as MVA-NP+M1How we know
- Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza VaccineTerminatedPhase 1University of OxfordNCT02014168Written as Viroflu® and MVA-NP+M1How we know
- A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy AdultsCompletedPhase 1University of OxfordNCT00942071Written as MVA-NP+M1How we know
- A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy AdultsCompletedPhase 2University of OxfordNCT00993083Written as MVA-NP+M1How we know